Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2023-03-16 Regulatory Filings
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-03-16 English
Regulatory Filings 2023
Regulatory Filings
2023-03-16 English
Regulatory Filings 2023
Regulatory Filings
2023-03-16 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-16 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. It includes details about the plans, the number of shares to be issued, and incorporates exhibits by reference. It is not a financial report, earnings release, or management discussion, but a registration statement related to capital raising through employee stock plans. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 7,000 characters and contains substantive content, not just an announcement or certification.
2023-03-13 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It is a prospectus describing the potential offering of securities such as common stock, preferred stock, debt securities, warrants, and units. The document is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or a brief summary. Hence, the classification is CAP with high confidence.
2023-03-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.